Whether finding new treatments for schizophrenia or first-time ways to tackle bladder cancer, these companies are finding ...

China: A recent multicenter randomized controlled trial has highlighted the potential benefits of acupuncture as a ...

Emerging evidence shows glucose-lowering medications may have the potential to improve chronic obstructive pulmonary disease ...

Dupilumab added to standard COPD triple therapy reduces the annual rate of moderate exacerbations but not severe exacerbations.

Dupilumab vs placebo was linked to improved health-related quality of life and respiratory symptoms in patients with COPD and T2 inflammation.

With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...

SAN MARCOS, CA, USA I March 18, 2025 I SMSbiotech has announced a significant milestone in its pursuit of its regenerative medicine technology, securing ...

Ohtuvayre has Food and Drug Administration (FDA) approval for the ongoing treatment of chronic obstructive pulmonary disease (COPD) in adults. Ohtuvayre belongs to the drug class phosphodiesterase ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

As the UK endures another harsh winter, plummeting temperatures and a surge in respiratory infections are placing strain on ...